Nykjaer A, Kjøller L, Cohen R L, Lawrence D A, Garni-Wagner B A, Todd R F, van Zonneveld A J, Gliemann J, Andreasen P A
Department of Medical Biochemistry, University of Aarhus, Denmark.
J Biol Chem. 1994 Oct 14;269(41):25668-76.
The alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein (alpha 2MR/LRP) binds several ligands, including complex between the two chain urokinase-type plasminogen activator (uPA) and type-1 plasminogen activator inhibitor (PAI-1), and the single chain zymogen pro-urokinase (pro-uPA). We have used truncated variants of uPA and PAI-1 as well as Fab fragments of monoclonal antibodies with known epitopes to identify regions in the uPA.PAI-1 complex and in pro-uPA involved in binding to alpha 2MR/LRP.uPA.PAI-1 complex bound with high affinity (EC50 about 0.4 nM) via contacts in the PAI-1 moiety as well as the uPA serine proteinase domain and the uPAA chain. Pro-uPA bound with lower affinity (EC50 about 10 nM), and efficient binding to alpha 2MR/LRP was dependent on contact with both the A chain and the serine proteinase domain. We analyzed the effect of complex formation with the urokinase receptor since this is the primary target for binding of uPA.PAI-1 and pro-uPA at the cell surface, and since it has been demonstrated that urokinase receptor-bound uPA.PAI-1 complex is internalized following interaction with alpha 2 MR/LRP (Nykjaer, A., Petersen, C. M., Møller, B., Jensen, P.H., Moestrup, S.K., Holtet, T.L., Etzerodt M., Thøgersen, H.C., Munch, M., Andreasen, P.A., and Gliemann, J. (1992) J. Biol. Chem. 267, 14543-14546). Soluble recombinant urokinase receptor blocked the binding of pro-uPA to alpha 2MR/LRP but caused only a slight reduction in the affinity for binding of uPA.PAI-1. Moreover, pro-uPA bound to the urokinase receptor at the cell surface was not internalized and degraded unless activated to uPA and complexed with PAI-1. We conclude that pro-uPA is protected against degradation via alpha 2MR/LRP when bound to uPAR due to shielding of a binding contact in the A chain, whereas the affinity of uPAR-bound uPA.PAI-1 complex for binding to alpha 2MR/LRP remains sufficient to allow rapid internalization and degradation.
α2-巨球蛋白受体/低密度脂蛋白受体相关蛋白(α2MR/LRP)可结合多种配体,包括双链尿激酶型纤溶酶原激活剂(uPA)与1型纤溶酶原激活剂抑制剂(PAI-1)之间的复合物,以及单链酶原尿激酶原(pro-uPA)。我们使用了uPA和PAI-1的截短变体以及具有已知表位的单克隆抗体的Fab片段,来确定uPA·PAI-1复合物和pro-uPA中参与与α2MR/LRP结合的区域。uPA·PAI-1复合物通过PAI-1部分以及uPA丝氨酸蛋白酶结构域和uPA A链中的接触,以高亲和力(EC50约为0.4 nM)结合。Pro-uPA以较低的亲和力(EC50约为10 nM)结合,并且与α2MR/LRP的有效结合依赖于与A链和丝氨酸蛋白酶结构域的接触。我们分析了与尿激酶受体形成复合物的影响,因为这是uPA·PAI-1和pro-uPA在细胞表面结合的主要靶点,并且已经证明尿激酶受体结合的uPA·PAI-1复合物在与α2 MR/LRP相互作用后会被内化(Nykjaer, A., Petersen, C. M., Møller, B., Jensen, P.H., Moestrup, S.K., Holtet, T.L., Etzerodt M., Thøgersen, H.C., Munch, M., Andreasen, P.A., and Gliemann, J. (199) J. Biol. Chem. 267, 14543 - 14546)。可溶性重组尿激酶受体可阻断pro-uPA与α2MR/LRP的结合,但仅使uPA·PAI-1结合亲和力略有降低。此外,细胞表面与尿激酶受体结合的pro-uPA不会被内化和降解,除非被激活为uPA并与PAI-1形成复合物。我们得出结论,pro-uPA在与uPAR结合时,由于A链中一个结合位点被屏蔽,可通过α2MR/LRP免受降解,而与uPAR结合的uPA·PAI-1复合物与α2MR/LRP结合的亲和力仍足以使其快速内化和降解。